References
- Statistics Sweden. Statistical Abstract of Sweden 1990. Statistics Sweden, Stockholm 1989
- OECD. Financing and Delivering Health Care: A Comparative Analysis of OECD Countries. OECD, Paris 1987
- Keys A. Seven Countries. Harvard University Press, Cambridge, Massachusetts 1980
- Kannel W B., Wolf P A., Garrison R J. The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease, Section 34, Some Risk Factors Related to the Annual Incidence of Cardiovascular Disease and Death Using Pooled Repeated Biennial Measurements, 30 Year Follow up. U.S. Department of Commerce, National Technical Information Service, Springfield 1987
- Dorr A E., Gundersen K, Schneider J C., Spencer T W., Martin W E. Colestipol hydrochloride in hypercholesterolaemic patients: effect on serum cholesterol and mortality. J Chron Dis 1978; 31: 5–14
- Dayton S, Pearce M L., Hashmoto S, Dixon W J., Tomiyasu D. A controlled clinical trial of a diet high in unsaturated fat in preventing complications of atherosclerosis. Circulation 1969; 39–40, 1–63
- Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trials results, I, reduction in incidence of coronary heart disease. JAMA 1984; 251: 351–64
- Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trials results, II, the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365–74
- Frick M H., Elo O, Haapa K, et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dislipidemia. N Engl J Med 1987; 317: 1237–45
- Committee of Principal Investigators. A cooperative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978; 40: 1069–1118
- Committee of Principal Investigators. World Health Organization cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Lancet 1990; i: 600–04
- Muldoon M F., Manuck S B., Matthews K A. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. Br Med J 1990; 301: 309–14
- Socialstyrelsens Expertgrupp. Socialstyrelsens expertmote ger rekommendationer: behandling av hyperlipidemi–kolesterols och triglyceriders bety-delse som riskfaktorer. Lakartidgningen 1988; 85: 3841–5
- Walldius G, Jungner I. Lämpligt med två gränsvärden vid diagnostik och behandling av högt serum-kolesterol. Läkartidningen 1988; 85: 3835–9
- Kristiansen I S., Eggen A E., Thelle D S. Cost-effectiveness of incremental programmes for lowering serum cholesterol concentration: is individual intervention worth while?. Br Med J 1991; 302: 1119–22
- Garber A M., Littenberg B, Sox H C., Wagner J L., Gluck M. Costs and health consequences of cholesterol screening for asymptomatic older Americans. Arch Intern Med 1991; 151: 1089–95
- Grover S A., Coupal L, Fahkry R, Suissa S. Screening for hypercholesterolemia among Canadians: how much will it cost?. Can Med Assoc J 1991; 144: 161–8
- Friedewald W T., Levy R I., Fredrickson D S. Estimation of the concentration of LDL cholesterol in plasma without use of the preparative ultracentri-fuge. Clin Chem 1972; 18: 499–502
- Danielsson B, Ekman R, Fex G, Johansson B G., Nilsson-Ehle P, Wadstein J. Changes in plasma high density lipoproteins in chronic male alcoholics during and after abuse. Scand J Clin Lab Invest 1978; 38: 113–9
- Johannesson M, Borgquist L, Jonsson B. The costs of treating hypertension in Sweden: an empirical investigation in primary health care. Scand J Prim Health Care 1991; 9: 155–60